Press Releases

Date Title
September 17, 2023 Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
September 7, 2023 Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023
August 31, 2023 Enanta Pharmaceuticals to Participate in Investor Conferences in September
August 7, 2023 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
July 31, 2023 Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023
June 20, 2023 Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
June 7, 2023 Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023
May 31, 2023 Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference
May 9, 2023 Enanta Pharmaceuticals to Participate in Two Investor Conferences in May
May 8, 2023 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
Displaying 1 - 10 of 24